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Background: The aim of this study was to investigate the molecular epidemiological characteristics of metallo-β-lactamase 
(MBL)-producing Pseudomonas aeruginosa clinical isolates in Korea.
Materials and Methods: Three hundred and twenty nine P. aeruginosa clinical isolates were collected from 23 general hospitals 
in Korea from March to June 2014. Species were identified by matrix-assited laser desorption/ionization-time of flight and 16S 
rRNA sequencing. Antimicrobial susceptibility was determined by disk diffusion methods. Further, minimum inhibitory concen-
trations of carbapenems were determined by Etest. Polymerase chain reaction and sequencing were performed to identify genes 
encoding MBLs. Multi-locus sequence typing and pulsed-field gel electrophoresis were performed to determine epidemiologi-
cal characteristics of MBL-producing P. aeruginosa isolates.
Results: Of the 329 isolates, 229 (69.6%) were susceptible to the carbapenems tested, including imipenem and meropenem; 
while 100 (30.4%) were non-susceptible to more than one of the carbapenems. Genes encoding imipenemase-6 (IMP-6) and 
Verona imipenemase-2 (VIM-2) MBLs were identified in 21 (6.4%) isolates (n = 17 and 4, respectively). All MBL-producing iso-
lates showed multi-drug resistant phenotype, and a majority (n = 19) of the isolates were identified as sequence type 235 (ST235). 
The remaining isolates (n = 2) were identified as ST309 and ST463.
Conclusion: P. aeruginosa ST235 might play an important role in dissemination of MBL genes in Korea.
Key Words: Pseudomonas aeruginosa; metallo-β-lactamase; VIM-2 metallo-β-lactamase; International clone; Multi-locus se-
quence typing
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Introduction
Carbapenems have widely been used as the mainstay for the 
treatment of severe infections caused by Pseudomonas aeru-
ginosa. This is because they can easily permeate through the 
porins on the outer membrane of these microorganisms. 
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Moreover, they have a high affinity for penicillin-binding pro-
teins and a structure resistant to hydrolytic activities of most 
β-lactamases [1]. Unfortunately, a carbapenem-resistant P. 
aeruginosa (CRPA) has now emerged and is disseminating 
worldwide. According to a survey conducted in Korea in 2011, 
imipenem (a carbapenem) resistance rate of P. aeruginosa 
was 22% among 15,032 clinical isolates [2]. In fact, CRPA is 
considered a significant clinical threat because CRPA clinical 
isolates usually exhibit co-resistance to other classes of anti-
microbial agents. Thus, there remain only a few alternatives 
for the treatment of systemic infections caused by carbapen-
em-resistant microorganisms [3].
Production of carbapenemase is the most important mech-
anism in P. aeruginosa for acquiring carbapenem resistance. 
Diverse kinds of carbapenemases have been identified in P. 
aeruginosa, including KPC and GES variants of class A; IMP-, 
VIM-, SPM-, and NDM-type metallo-β-lactamases (MBLs) of 
class B; OXA-40 and OXA-198 enzymes of class D [4-12]. 
MBL-producing P. aeruginosa (MPPA) has repeatedly been 
identified in Korea, since the first report for VIM-2 MPPA clini-
cal isolates in 2002 [6]. A study in 2009 reported that IMP-6 was 
the dominant MBL (7.8%, 30/386) in P. aeruginosa clinical iso-
lates collected in Korea followed by VIM-2 (0.3%, 1/386) [13].
A multi-locus sequence typing (MLST) scheme for P. aeru-
ginosa proposed by Curran et al. [14] has facilitated compari-
sons of epidemiological characteristics of strains from differ-
ent hospitals or countries. Earlier studies reported that two 
international P. aeruginosa clonal complexes (CCs), CC111 
and CC235, played a major role in dissemination of MBL 
genes worldwide [15, 16]. However, only a few studies have 
performed MLST experiments on MPPA in Asian countries. P. 
aeruginosa sequence type 235 (ST235) and ST357 producing 
IMP-1 MBL were identified in Japan [17]. P. aeruginosa ST235 
producing IMP-6 or VIM-2 were also identified in Korea [13]. 
Furthermore, a recent study identified MPPA isolates of ST235 
from Malaysia, Thailand, Sri Lanka, and Korea; ST773 from In-
dia, and ST298 from Taiwan [18].
The present study was conducted to investigate the molecu-
lar epidemiological characteristics of MPPA clinical isolates in 
Korea.
Materials and Methods
1. Bacterial strains and susceptibility testing
Non-duplicate P. aeruginosa clinical isolates (n = 329) were 
collected from 23 hospitals across 15 cities in Korea (Fig. 1) 
from March to June, 2014. The isolates were recovered from 
respiratory specimens (n = 120), urine (n = 96), pus (n = 78), 
blood (n = 24), and others (n = 11) (Table 1). Species identifi-
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  http://dx.doi.org/10.3947/ic.2015.47.1.33  •  Infect Chemother 2015;47(1):33-40www.icjournal.org 35
cation was performed using the Bruker MALDI Biotyper 
(Bruker, Billerica, MA, USA) and 16S rRNA gene sequencing. 
Antimicrobial susceptibilities were tested by disk diffusion 
method following the Clinical and Laboratory Standards Insti-
tute (CLSI) guidelines [19]. Antimicrobial agents tested were 
amoxicillin-clavulanate, piperacillin-tazobactam, ticarcil-
lin-clavulanate, aztreonam, ceftazidime, cefepime, imipenem, 
meropenem, amikacin, gentamicin, tobramycin, trimetho-
prim-sulfamethoxazole, ciprofloxacin, tetracycline, and colis-
tin. Minimum inhibitory concentrations (MICs) of imipenem 
Table 1. Antimicrobial susceptibilities of Pseudomonas aeruginosa clinical isolates by specimen
 
 
 
No. of isolates  (%)
Respiratory 
(n = 120)
Blood 
(n = 24)
Urine 
(n = 96)
Pus 
(n = 78)
Other 
(n = 11)
Total 
(n = 329)
S R S R S R S R S R S R
AMC      0 (0) 120 (100)    0 (0) 24 (100)   0 (0) 96 (100)   0 (0) 78 (100)   0 (0) 11 (100)      0 (0) 329 (100)
TZP 101 (84.2)   19 (15.8) 20 (83.3)   4 (16.7) 72 (75.0) 22 (22.9) 64 (82.1) 14 (17.9)   9 (81.8)   2 (18.2) 266 (80.9)   61 (18.5)
TIM   98 (81.7)   22 (18.3) 21 (87.5)   3 (12.5) 66 (68.7) 30 (31.3) 60 (76.9) 18 (23.1)   8 (72.7)   3 (27.3) 253 (76.9)   76 (23.1) 
ATM   75 (62.5)   29 (24.2) 12 (50.0)   8 (33.3) 54 (56.2) 26 (27.1) 48 (61.5) 19 (24.4)   8 (72.7)   3 (27.3) 197 (59.9)   85 (25.8)
CAZ   87 (72.5)   21 (17.5) 18 (75.0)   4 (16.7) 62 (64.6) 28 (29.2) 56 (71.8) 16 (20.5)   7 (63.6)   4 (36.4) 230 (69.9)   73 (22.2)
FEP   87  (72.5)   15 (12.5) 16 (66.7)   3 (12.5) 56 (58.3) 30 (31.3) 60 (77.0)   9 (11.5)   7 (63.6)   3 (27.3) 226 (68.7)   60 (18.2)
IPM   81 (67.5)   38 (31.7) 18 (75.0)   5 (20.8) 63 (65.6) 31 (32.3) 62 (79.5) 16 (20.5)   6 (54.5)   4 (36.4) 230 (69.9)   94 (28.6)
MEM   84 (70.0)   27 (22.5) 20 (83.3)   3 (12.5) 64 (66.6) 30 (31.3) 62 (79.5) 13 (16.7)   6 (54.5)   3 (27.3) 236 (71.7)   76 (23.1)
AMK 111 (92.5)     8 (6.7) 23 (95.8)   1 (4.2) 69 (71.9) 27 (28.1) 72 (92.3)   5 (6.4) 10 (90.9)   1 (9.1) 285 (86.6)   42 (12.8)
GEN 103 (85.9)   13 (10.8) 21 (87.5)   3 (12.5) 65 (67.7) 28 (29.2) 67 (85.9) 11 (14.1) 10 (90.9)   1 (9.1) 266 (80.9)   56 (17.0)
TOB 104 (86.6)   14 (11.7) 20 (83.3)   3 (12.5) 68 (70.8) 28 (29.2) 65 (83.3) 12 (15.4)   9 (81.8)   2 (18.2) 266 (80.9)   59 (17.9)
TMP/SMT      0 (0) 120 (100)   0 (0) 24 (100)   0 (0) 96 (100)   0 (0) 78 (100)   0 (0) 11 (100)      0 (0) 329 (100)
CIP   78 (65.0)   38 (31.7) 15 (62.5)   8 (33.3) 53 (55.2) 41 (42.7) 51 (65.4) 24 (30.8)   9 (81.8)   2 (18.2) 206 (62.6) 113 (34.3)
TET     2 (1.7) 116 (96.6)   0 (0) 24 (100)    1 (1.0) 95 (99.0)   0 (0) 78 (100)   0 (0) 11 (100)      3 (0.9) 324 (98.5)
CST 120 (100)     0 (0) 24 (100)   0 (0) 96 (100)   0 (0) 78 (100)   0 (0) 11 (100)   0 (0) 329 (100)      0 (0)
S, susceptible; R, resistant; AMC, amoxicillin-clavulanic acid; TZP, piperacillin-tazobactam; TIM, ticarcillin-clavulanic acid; ATM, aztreonam; CAZ, ceftazidime; FEP, cefepime; 
IPM, imipenem; MEM, meropenem; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; TMP/SMT, trimethoprim-sulfamethoxazole; CIP, ciprofloxacin; TET, tetracycline; 
CST, colistin.
Table 2. Nucleotide sequences of primers used in this study
Primer name Target gene Nucleotide sequence  (5’ to 3’) Product size  (bp) Reference
KPC-F KPC-type GTCACTGTATCGCCGTCTAGTTC
909 This study
KPC-R TGGTGGGCCAATAGATGATT
GES-F GES-type CGCTTCATTCACGCACTATT
855 20
GES-R GTCCGTGCTCAGGATGAGTT
IMP-1F IMP-1-type AAGGCGTTTATGTTCATACTTCG
605 This study
IMP-1R TTTAACCGCCTGCTCTAATGTAA
VIM-2F VIM-2-type ATCATGGCTATTGCGAGTCC
749 21
VIM-2R ACGACTGAGCGATTTGTGTG
NDM-F NDM-type GCCCAATATTATGCACCCGG
738 This study
NDM-R CTCATCACGATCATGCTGGC
OXA-48F OXA-48-type GATTATCGGAATGCCTGCGG
845 20
OXA-48R CTACAAGCGCATCGAGCATCA
KPC, klebsiella pneumoniae  carbapenemase; F, forward; R, reverse; GES, greece extended-spectrum β-lactamase; IMP, imipenemase; VIM, Verona imipenemase; NDM, 
New Delhi metallo-β-lactamase; OXA, oxacillinase.
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and meropenem were determined by Etest on Mueller-Hinton 
agar (Becton, Dickinson and Company, Sparks, MD, USA) ac-
cording to manufacturer’s instruction.
2. Characterization of carbapenemase genes
Carbapenemase genes were detected by PCR using primers 
as previously described (for genes encoding KPC, VIM-2-, and 
OXA-48-type carbapenemases) [20, 21] and those designed in 
this study (for genes encoding GES-, IMP-1-, and NDM-type 
carbapenemases) (Table 2). Templates for PCR amplification 
from clinical isolates were whole cell lysates, and amplified 
products were subjected to direct sequencing. Both strands of 
the PCR product were sequenced twice with an automatic se-
quencer (model 3730xl; Applied Biosystems, Weiterstadt, Ger-
many). Experimentally determined nucleotide sequences 
were compared to sequence databases using BLAST (http://
blast.ncbi.nlm.nih.gov/).
3. Multi-locus sequence typing (MLST) 
PCR and sequencing for 7 housekeeping genes (acsA, aroE, 
guaA, mutL, nuoD, ppsA, and trpE) were performed as de-
scribed previously [14]. Experimentally determined nucleo-
tide sequences of both strands were compared to pre-existing 
sequences in the MLST database to assign allelic numbers 
and STs (http://pubmlst.org/paeruginosa).
4. Pulse-field gel electrophoresis (PFGE)
XbaI-digested genomic DNA was prepared and DNA frag-
ments were separated for 20 h at 6 V/cm at 11°C using the 
CHEF-DRII System (Bio-Rad, Hercules, CA, USA) with initial 
and final pulse times of 0.5 s and 30 s, respectively [13]. A 
lambda ladder (Bio-Rad) was used as DNA size marker. Band 
patterns were analyzed with UVIband/Map software (UVItech 
Ltd, Cambridge, UK) to generate a dendrogram based on the 
unweighted pair group method using arithmetic averages 
from the Dice coefficient.
Results
1.  Antimicrobial susceptibilities of P. aeruginosa 
clinical isolates
Out of the 329 P. aeruginosa clinical isolates, 229 (69.6%) 
were found to be susceptible to the carbapenems tested, in-
cluding imipenem and meropenem; while 100 (30.4%) were 
Table 3. Antimicrobial susceptibilities of Pseudomonas aeruginosa  clinical isolates
No. of isolates  (%)
Carbapenem-susceptible  
(n = 229)
Carbapenem-non-susceptible  
(n = 100)
Total  
(n = 329) 
Susceptible Intermediate Resistant Susceptible Intermediate Resistant Susceptible Intermediate Resistant
Amoxicillin- 
  clavulanate
0 (0) 0 (0) 229 (100) 0 (0) 0 (0) 100 (100) 0 (0) 0 (0) 329 (100)
Piperacillin- 
  tazobactam
215 (93.9) 0 (0)   14 (6.1) 51 (51) 2 (2) 47 (47) 266 (80.9)  2 (0.6) 61 (18.5)
Ticarcillin- 
  clavulanate
208 (90.8) 0 (0)   21 (9.2) 45 (45) 0 (0) 55 (55) 253 (76.9) 0 (0) 76 (23.1)
Aztreonam 174 (76.0)    24 (10.5)     31 (13.5) 23 (23) 23 (23) 54 (54) 197 (59.9)    47 (14.3) 85 (25.8)
Ceftazidime 193 (84.3) 15 (6.5)   21 (9.2) 37 (37) 11 (11) 52 (52) 230 (69.9) 26 (7.9) 73 (22.2)
Cefepime 194 (84.7)    26 (11.4)    9 (3.9) 32 (32) 17 (17) 51 (51) 226 (68.7)    43 (13.1) 60 (18.2)
Imipenem 229 (100) 0 (0) 0 (0) 1 (1) 5 (5) 94 (94) 230 (69.9)    5 (1.5) 94 (28.6)
Meropenem 229 (100) 0 (0) 0 (0) 7 (7) 17 (17) 76 (76) 236 (71.7)   17 (5.2) 76 (23.1)
Amikacin 222 (97.0)    1 (0.4)  6 (2.6) 63 (63) 1 (1) 36 (36) 285 (86.6)      2 (0.6) 42 (12.8)
Gentamicin 209 (91.2)    6 (2.7) 14 (6.1) 57 (57) 1 (1) 42 (42) 266 (80.9)     7 (2.1) 56 (17.0)
Tobramycin 211 (92.1)    2 (0.9) 16 (7.0) 55 (55) 2 (2) 43 (43) 266 (80.9)     4 (1.2) 59 (17.9)
Trimethoprim- 
  sulfamethoxazole
0 (0) 0 (0) 229 (100) 0 (0) 0 (0) 100 (100) 0 (0) 0 (0) 329 (100)
Ciprofloxacin 186 (81.2)     5 (2.2)  38 (16.6) 20 (20) 5 (5) 75 (75) 206 (62.6) 10 (3.1) 113 (34.3)
Tetracycline   2 (0.9) 0 (0) 227 (99.1) 1 (1) 2 (2) 97 (97)    3 (0.9)   2 (0.6) 324 (98.5)
Colistin 229 (100) 0 (0) 0 (0) 100 (100) 0 (0) 0 (0) 329 (100) 0 (0) 0 (0)
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non-susceptible to more than one of the carbapenems (Table 3). 
Further, 92 of these 100 isolates exhibited non-susceptibility 
to both imipenem and meropenem. However, 7 imipenem-re-
sistant isolates exhibited susceptibility to meropenem while 
only a single meropenem isolate was susceptible to imipen-
em. Compared with carbapenem-susceptible isolates, carbap-
enem-non-susceptible isolates exhibited higher resistance 
rates to ceftazidime (9.2% versus 52%), cefepime (3.9% versus 
51%), amikacin (2.6% versus 36%), gentamicin (6.1% versus 
42%), tobramycin (7% versus 43%), and ciprofloxacin (16.6% 
versus 75%). Additionally, the 329 isolates were susceptible to 
colistin. Antimicrobial susceptibility rates, by specimen, are 
described in Table 1.
2. Identification of MBL genes
PCR amplification and subsequent sequence analyses identi-
fied the blaIMP-6 and the blaVIM-2 in 5.2% (n = 17) and 1.2% (n = 4) 
carbapenem-non-susceptible isolates, respectively (Table 4). 
None of the isolates showed positive results when amplified 
for the detection of genes encoding KPC-, GES-, NDM, and 
OXA-48-type carbapenemases.
3. Characteristics of MPPA clinical isolates
All MPPA clinical isolates were identified as ST235 (38-11-3-
13-1-2-4), except one isolate (BC3) of ST463 (6-5-5-3-1-6-3) 
producing IMP-6 and another (UUS4) of ST309 (13-8-9-3-1-
17-15) producing VIM-2 (Table 4). Moreover, all MPPA ST235 
isolates exhibited similar (>80% similarity) XbaI-macrorestric-
tion banding patterns by PFGE, while MPPA of ST463 and 
ST309 isolates displayed different (<70% similarity) patterns 
(Fig. 2). Further, all MPPA clinical isolates presented multi-
drug resistant phenotype in addition to high MIC values (>32 
mg/L) for both imipenem and meropenem. UUS4 was the 
only exception that showed a low MIC value (2 mg/L) for 
meropenem (Table 4).
Table 4. Characteristics of Pseudomonas aeruginosa clinical isolates producing metallo-β-lactamase
Isolate ST
MBL
genotype
MIC (mg/L)
Co-resistant to:
IPM MEM
GS8 235 blaIMP-6 >32 >32 AMK, AMC, ATM, FEP, CAZ, CIP, GEN, TET, TIM, TOB, TMP/SMT
CSU13 235 blaIMP-6 >32 >32 AMC, ATM, FEP, CAZ, CIP, TZP, TET, TIM, TMP/SMT
UUS6 235 blaIMP-6 >32 >32 AMK, AMC, ATM, FEP, CAZ, CIP, GEN, TZP, TET, TIM, TOB, TMP/SMT
UUS7 235 blaIMP-6 >32 >32 AMK, AMC, ATM, FEP, CAZ, CIP, GEN, TZP, TET, TIM, TOB, TMP/SMT
UUS15 235 blaIMP-6 >32 >32 AMK, AMC, ATM, FEP, CAZ, CIP, GEN, TZP, TET, TIM, TOB, TMP/SMT
CMSEO8 235 blaIMP-6 >32 >32 AMK, AMC, ATM, FEP, CAZ, CIP, GEN, TET, TIM, TOB, TMP/SMT
CNU7 235 blaIMP-6 >32 >32 AMK, AMC, ATM, FEP, CAZ, CIP, GEN, TET, TIM, TOB, TMP/SMT
SCHGM7 235 blaIMP-6 >32 >32 AMK, AMC, ATM, FEP, CAZ, CIP, GEN, TZP, TET, TIM, TOB, TMP/SMT
CMEUI9 235 blaIMP-6 >32 >32 AMC, ATM, FEP, CIP, TET,  TMP/SMT
CMDAE14 235 blaIMP-6 >32 >32 AMK, AMC, ATM, FEP, CAZ, CIP, GEN, TZP, TET, TIM, TOB, TMP/SMT
BUPAIK7 235 blaIMP-6 >32 >32 AMK, AMC, ATM, FEP, CAZ, CIP, GEN, TZP, TET, TIM, TOB, TMP/SMT
BUPAIK15 235 blaIMP-6 >32 >32 AMK, AMC, ATM, FEP, CAZ, CIP, GEN, TET, TIM, TOB, TMP/SMT
JNU2 235 blaIMP-6 >32 >32 AMK, AMC, FEP, CAZ, CIP, GEN, TZP, TET, TIM, TOB, TMP/SMT
JNU3 235 blaIMP-6 >32 >32 AMK, AMC, FEP, CAZ, CIP, GEN, TZP, TET, TIM, TOB, TMP/SMT
JNU13 235 blaIMP-6 >32 >32 AMK, AMC, FEP, CAZ, CIP, GEN, TET, TIM, TOB, TMP/SMT
JBNU1 235 blaIMP-6 >32 >32 AMK, AMC, ATM, FEP, CAZ, CIP, GEN, TZP, TET, TIM, TOB, TMP/SMT
BC3 463 blaIMP-6 >32 >32 AMK, AMC, ATM, FEP, CAZ, CIP, GEN, TET, TIM, TOB, TMP/SMT
JBNU5 235 blaVIM-2 >32 >32 AMK, AMC, CAZ, CIP, GEN, TZP, TET, TIM, TOB, TMP/SMT
JBNU9 235 blaVIM-2 >32 >32 AMK, AMC, ATM, FEP, CAZ, CIP, GEN, TZP, TET, TIM, TOB, TMP/SMT
CMIN8 235 blaVIM-2 >32 >32 AMC, FEP, CAZ, TET, TIM, TMP/SMT
UUS4 309 blaVIM-2 >32 2 AMK, AMC, ATM, FEP, CAZ, CIP, GEN, TET, TIM, TOB, TMP/SMT
ST, sequence type; MBL, metallo-β-lactamase; MIC, minimum inhibitory concentration; IPM, imipenem; MEM, meropenem; AMK, amikacin; AMC, amoxicillin-clavulanic 
acid; ATM, aztreonam; FEP, cefepime; CAZ, ceftazidime; CIP, ciprofloxacin; GEN, gentamicin; TET, tetracycline; TIM, ticarcillin-clavulanic acid; TOB, tobramycin; TMP/SMT, 
trimethoprim-sulfamethoxazole; TZP, piperacillin-tazobactam. 
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Discussion
A molecular epidemiological study in 2008, based on a sur-
vey of 205 non-duplicated P. aeruginosa clinical isolates, col-
lected from 18 university hospitals across 8 provinces of Ko-
rea, identified them as 62 different STs. Of these, 47.8% isolates 
(n = 98) were identified as CC235. These, in turn, comprised of 
ST235 (n = 96) and two single-locus ST235 variants- ST1015 (n 
= 1) and ST1162 (n = 1). The remaining isolates (n = 107) were 
identified as 59 different STs, including ST111, ST170, ST244, 
ST591, ST641, ST708, ST773, ST829, ST983, ST1015, ST1154, 
ST1162, and ST1166, sharing alleles with ST235 at less than 5 
out of the 7 loci [22].
We previously reported (based on a survey in 2009) that 
clonal dissemination of MPPA ST235 is the principal cause for 
the diffusion of IMP-6 and VIM-2 MBL genes in Korea [13]. 
Despite a 5-year interval, our present study shows results sim-
ilar to the previous survey. Compared with the earlier report, 
prevalence of MPPA is slightly lower in this study- from 8.0% 
(31/386) to 6.4% (21/329). This is due to lower prevalence of 
IMP-6- from 7.8% (30/386) to 5.2% (17/329). Although the 
prevalence of VIM-2 increased marginally from 0.3% (1/386) 
to 1.2% (4/329), IMP-6 was still the dominant MBL type in P. 
aeruginosa in Korea. The antimicrobial susceptibility rates of 
P. aeruginosa clinical isolates, recovered from blood speci-
mens, for imipenem (18/24, 75.0%) and meropenem (20/24, 
83.3%) were higher compared to those recovered from speci-
mens other than blood, including respiratory, urinary, and 
wound specimens, (212/305, 69.5%; and 216/305, 70.8%, re-
spectively) (Table 1).
Interestingly, new MPPA clones emerged in our current 
study. In the previous survey, all the MPPA clinical isolates (n = 
31) were identified as ST235. Although ST235 continues to be 
the dominant strain among MPPA clinical isolates in this 
study, we identified two isolates as different STs- ST309 and 
ST463. MPPA ST235 has been identified in many Asian coun-
tries, including Japan, Malaysia, Thailand, Sri Lanka, and Korea 
[17, 18]. However, there are other MPPA strains that have also 
been identified in Asian countries: ST357 in Japan, ST773 in 
India, and ST298 in Taiwan. Recently, dissemination of IMP-6 
MPPA ST244 in China was reported [23]. There is no evidence 
though, whether MPPA ST309 and ST463 entered Korea from 
foreign countries, or the strains acquired the MBL gene by hor-
izontal transfer in this country itself. Nevertheless, what is 
alarming is that diversification of MPPA strains in Korea might 
be a signal for further dissemination of MPPA in the country.
In conclusion, our study underscores the findings that IMP-
6 MPPA ST235 has disseminated in Korea, and that new MPPA 
strains, ST309 and ST463, have surfaced in the country. Given 
the impending hazards of these phenomena, it is crucial to 
monitor changes in MBL types and MPPA strains through pe-
riodic surveys for MPPA.
Figure 2. XbaI -macrore-
striction patterns of metallo-
β-lactamase-producing 
Pseudomonas aeruginosa 
clinical isolates.
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